Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00400374 · ClinicalTrials.gov registry record · Phase 1
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00400374 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 10 participants.
The verdict
NCT00400374, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).
Interventions
- DRUG Celecoxib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00400374
The ClinicalTrials.gov registry entry for NCT00400374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00400374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00400374 about?
NCT00400374 is a clinical study titled "Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2". This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).
What is the current status of trial NCT00400374?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00400374?
The interventions under investigation include: Celecoxib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00400374?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.